Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,138.80
(
-0.49%
)
US TECH 100
26,370.00
(
-0.75%
)
Dow Jones
49,141.93
(
-0.34%
)
Brent Oil
103.79
(
-0.60%
)
Bitcoin
76,374.89
(
0.04%
)
News Focus
News Focus
Post# of 257458
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122898
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 233337

Thursday, 07/07/2022 12:23:41 PM

Thursday, July 07, 2022 12:23:41 PM

Post# of 257458
ICPT will resubmit Ocaliva NDA in NASH based_on_new_data_analyses:

https://www.globenewswire.com/news-release/2022/07/07/2475765/23024/en/Intercept-Announces-Positive-Data-in-Fibrosis-due-to-NASH-from-a-New-Analysis-of-its-Phase-3-REGENERATE-Study-of-Obeticholic-Acid-OCA.html

Good look with that! New data analyses can’t alter the fact that Ocaliva is simply a bad drug for NASH.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today